Home
Products & Services
Support
About
Contact Us
FinancialContent is the trusted provider of stock market information to the media industry.
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Dynavax Technologies (NQ: DVAX)
4.100 USD  +0.290 (+7.61%)
Official Closing Price  /  Updated: 4:48 PM EDT, Jun 17, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 1,927,300
Open 3.840
Bid (Size) 3.100 (1)
Ask (Size) 4.740 (1)
Prev. Close 3.810
Today's Range 3.830 - 4.250
52wk Range 3.570 - 16.35
Shares Outstanding 62,274,096
Dividend Yield N/A
Performance
YTD
-56.61%
-56.61%
1 Month
-32.01%
-32.01%
3 Month
-47.30%
-47.30%
6 Month
-59.61%
-59.61%
1 Year
-74.29%
-74.29%
Top News
More News
Dynavax to Present at the William Blair & Co. Annual Growth Stock Conference
Dynavax Technologies Corporation (NASDAQ: DVAX), today announced that Ryan Spencer, Senior Vice President, Commercial, and Interim Co-President, will present at the William Blair & Co. Annual Growth... Read More
from GlobeNewswire News Releases
Overall Response Rate of 76% in Advanced Melanoma Patients with Dynavax’s SD-101 in Combination with KEYTRUDA® (pembrolizumab); Data Presented Today at the 2019 ASCO Annual Meeting
Dynavax Technologies Corporation (NASDAQ: DVAX), today announced increasingly favorable results from the Phase 1b/2 (SYNERGY-001), open-label, multicenter study of the combination of SD-101 and... Read More
from GlobeNewswire News Releases
More News
Read More
Dynavax Presents Phase 2 Data on SD-101 in Combination with KEYTRUDA® (pembrolizumab) for Patients with Head and Neck Squamous Cell Carcinoma at the 2019 ASCO Annual Meeting
from GlobeNewswire News Releases
Dynavax Announces Strategic Restructuring to Focus on its Vaccine Business
from GlobeNewswire News Releases
Dynavax Announces First Quarter 2019 Financial Results
from GlobeNewswire News Releases
UPDATE 2-VBI's shares plunge after hep B vaccine fails secondary goal in late-stage trial
category companyNews
from Reuters: Company News
RSI Alert: Dynavax Technologies (DVAX) Now Oversold
category Stocks
from Market News Video
Recent 52-Week Low Surpassed in Shares of Dynavax Technolo (DVAX)
from Comtex SmarTrend® News Briefs
Here's Why Dynavax Technologies Is Tumbling
category MRK , Market News , DVAX
from Motley Fool
Why Dynavax Technologies Stock Is Soaring Today
category DVAX , Market News
from Motley Fool
Dynavax Technologies Corp (DVAX) Q1 2019 Earnings Call Transcript
category DVAX , Market News
from Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
   
© Copyright FinancialContent Services, Inc.